CRISPR Therapeutics AG (CRSP) Shares Outstanding (2015 - 2026)

CRISPR Therapeutics AG has reported Shares Outstanding (Entity) for 12 years, with the latest figure at $96.4 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 11.61% year-over-year to $96.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.4 million (up 11.61% YoY) and the FY2025 annual result came in at $95.9 million, up 11.84% from the prior year.
• Shares Outstanding (Entity) rose to $96.4 million in Q1 2026 per CRSP's latest filing, from $95.9 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $96.4 million in Q1 2026 and troughed at $77.4 million in Q1 2022.
• A 5-year average of $84.2 million and a median of $84.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) gained 1.51% in 2023, then increased 11.84% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $78.5 million in 2022, then rose by 1.95% to $80.0 million in 2023, then grew by 7.12% to $85.7 million in 2024, then climbed by 11.84% to $95.9 million in 2025, then gained by 0.51% to $96.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $96.4 million, $95.9 million, and $93.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.